Advantages of Innovotherapy over probe-based treatments (in relation to Urogynecol Infections)
Innovotherapy is clinically proven to be safer (in relation to Urogynecol Infections) than other electrical muscle stimulation therapies that claim to treat urinary incontinence.
A randomised controlled trial1 (n=52) on the efficacy of probe-based pelvic floor electrical stimulation in the treatment of SUI carried out at the Evanston Continence Center in Illinois, noted 21 adverse events. These ranged from vaginal irritation, pain, and vaginal and urinary tract infections and were experienced both by users of active and inactive/sham probes. This study saw a very high dropout rate of 15%.
A second single-arm study2 on the use of a probe-based device to treat pelvic floor muscle weakness, by Dr Scott Eder of the Center for Women’s Health and Wellness, New Jersey, reported 31 adverse incidents amongst 83 subjects and a dropout rate of 17%.
These studies highlight the risks associated with using probe-based devices as an intervention in patients with stress urinary incontinence.
Advantages of Innovotherapy
- Global recruitment of pelvic floor muscles
- Low current density allows for comfortable but effective current levels
- Stimulation can be delivered while in the standing or lying position
- Minimal risk of adverse side effects
- Research conducted to date consistently confirms improvements in key outcomes, symptoms and acceptability
- Comfortable, easy to administer treatment will encourage patient compliance
In summary, INNOVO® delivers effective, safe and comfortable global recruitment of the pelvic floor.
Stimulation of the pelvic floor muscles using a probe-based device3:
Stimulation of the pelvic floor muscles using Innovotherapy: